Business · 07/08/2019Updated: 10/17/2026 · 1 min read
FDA Establishes Public Docket for Oligonucleotide Therapeutics Evaluation
Summary
The FDA is seeking public comments on the clinical pharmacology of oligonucleotide therapeutics, focusing on hepatic and renal impairment, drug-drug interactions, and immunogenicity, to inform study design and regulatory assessment.